About
MYmAb Biologics
Malaysian Cancer Researchers Pioneering in Tissue Microarray Technology
MYmAb Biologics is a life sciences company focused on contributing to the acceleration of drug discovery, diagnostics, and fundamental research. Our diverse team of experts shares a common goal: to enhance the quality of life and extend patient lifespans.
Our mission is to facilitate research, to fuel cutting-edge research, and enable speedy bench-to-bedside translation. We proudly support the global scientific community by supplying high-quality tissue microarrays and antibodies. Our products are essential tools for researchers striving to make significant contributions to medical science.
At MYmAb Biologics, we specialise in developing novel anti-glycan monoclonal antibodies. Our cutting-edge research targets a wide range of cancers and infectious diseases, offering new hope for effective treatments and diagnosis.
The Purpose Behind Our Actions
Mission
Our mission is to facilitate research, to fuel cutting-edge research and enable speedy bench to bedside translation.
Vision
Our vision is to help extend cancer patients’ lifespan and improve their quality of life.
MYmAb Biologics' Leadership Team
Meet the team of experts behind MYmAb Biologics who are committed to fighting cancer by contributing their knowledge and experience in cancer reseach.
Director
Datuk Seri Pang Chee Khiong
As the Executive Chairman of Fibon Berhad, Datuk Seri Pang is a skilled business leader with an accomplished career spanning more than 32 years. His extensive experience and strategic vision have been instrumental in guiding our company towards growth and innovation.
Executive Director, Founder, and Chief Executive Officer
Associate Professor Chua Jia Xin
Dr. Chua, with over 15 years of experience in translational oncology focusing on monoclonal antibodies, cancer vaccines and histopathology, honed her expertise during 12 years in academia and industry in UK before returning to Malaysia. She founded MYmAb Biologics Sdn. Bhd. and currently serves as an Associate Professor at Universiti Tunku Abdul Rahman. In 2015, Medicine Innovate recognised her research as a key contribution to global biomedical excellence. In 2022, she published a paper on SARS-CoV-2 linked to the United Nations Sustainable Development Goals.
Director and Head of Sales and Marketing
Miss Pang ZhiWei
Miss Pang has more than 10 years of experience in sales and marketing. She plays a distinct role in attracting potential customers, driving company’s growth, revenue, and overall success.
Scientific Advisor
Professor Lindy Gillian Durrant
Prof. Durrant is an internationally recognised immunologist specialising in tumour therapy and the co-founder of Scancell Ltd. in Oxford, UK. With over 25 years of experience in translational research, she has developed numerous products for clinical trials, including monoclonal antibodies and cancer vaccines. Currently holding a Chair in Cancer Immunotherapy in the Department of Clinical Oncology at the University of Nottingham, her contributions were honoured with the Swedish Society of Oncology Waldenstrom Prize in 2019.
Scientific Advisor
Professor Lai Oi Ming
Prof Lai. is a biotechnologist with 22 years of experience in structured lipids and bioprocess technology. She leads the Natural Products and Medicine Research (Bioprocess 10) Laboratory, Institute of Bioscience, UPM. In 2019, she was awarded the ‘’National Academic Award’’ and ‘’National Intellectual Property Award’’.
Medical Advisor
Doctor Chua Peng Teng
Dr. Chua is a specialist in Obstetrics & Gynaecology, with sub-specialisation in Minimally Invasive Gynaecologic Surgery. His clinical focus includes female cancers as well as advanced pelvic surgeries. He is a clinical fellow of APAGE-MIT and is an active Fellow of the American College of Surgeons (FACS). Dr Chua is an experienced clinician and surgeon involved in surgical research and medical education for the Asia Pacific Region. Recently, he was appointed as the chairman of APAGE-YAG (Young Apage Group), representing fellows and young surgeons in the Asia Pacific Association for Gynaecologic Endoscopy & Minimally Invasive Therapy (APAGE-MIT).
Company Advisor
Professor Emeritus Tan Sri Dato’ Doctor Syed Jalaludin Syed Salim
Tan Sri Syed is a leading academician and senior fellow of the Academy of Sciences Malaysia with vast experience in corporate affairs. Tan Sri started his corporate career in the oil and gas industries as an independent member of ESSO Bhd. and later Preton Bhd. Tan Sri was the longest chairman of Bank Rakyat Malaysia and founding director of the Capital Market Development Fund Board. He also holds various positions in both Public and Private universities.
Our Publications
Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination
The emergence of SARS-CoV-2 variants raises concerns of reduced COVID-19 vaccine efficacy. Our study suggests that vaccines that induce broader sterilising immunity are essential to fight against fast-emerging variants.
Contact Our Team
Location:
Block D-G-8, UPM-MTDC Technology Centre III, Universiti Putra Malaysia, 43400 Serdang, Selangor Darul Ehsan, Malaysia.
Phone:
03-8938 9819
Email:
info.mymab@gmail.com